Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer.
In the randomized phase II trial, researchers evaluated Elenagen, a plasmid therapy—a small, circular piece of DNA encoding the protein p62/SQSTM1—administered in combination with the standard chemotherapy gemcitabine in women with PROC and elevated CA-125.
Scientists from the UF Health Cancer Institute have found a way to make treatment for a notoriously aggressive breast cancer more effective.
Of all the types of breast cancer, triple negative breast cancer is the most aggressive and lacks specific therapies. TNBC also is more likely to metastasize, or travel through the blood stream to spread to other organs, which causes most of breast cancer-related deaths each year.
Researchers from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators analyzed 692 clinical trials launched between 2000 and 2024.
A multi-institutional research team has developed one of the first validated tools to predict before treatment if a patient will have a favorable biochemical response in patients with metastatic hormone-sensitive prostate cancer.
Researchers set out to answer a question: what is the ideal duration of hormone therapy for the treatment of prostate cancer? Hormone therapy is commonly combined with radiation therapy for prostate cancer, but patients are often unsure how long it should be continued and why.
Johnson & Johnson announced positive topline results from the investigational phase III MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide.
Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Positive results were announced from its two pivotal phase III trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B in over 1,800 patients from 29 countries.
